GSK PLC-SPON ADR (GSK) Fundamental Analysis & Valuation

NYSE:GSK • US37733W2044

Current stock price

56.69 USD
+0.7 (+1.25%)
At close:
56.9 USD
+0.21 (+0.37%)
After Hours:

This GSK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. GSK Profitability Analysis

1.1 Basic Checks

  • In the past year GSK was profitable.
  • In the past year GSK had a positive cash flow from operations.
  • GSK had positive earnings in each of the past 5 years.
  • Each year in the past 5 years GSK had a positive operating cash flow.
GSK Yearly Net Income VS EBIT VS OCF VS FCFGSK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • GSK has a better Return On Assets (9.35%) than 90.63% of its industry peers.
  • GSK has a Return On Equity of 34.90%. This is amongst the best in the industry. GSK outperforms 95.83% of its industry peers.
  • GSK has a Return On Invested Capital of 19.80%. This is amongst the best in the industry. GSK outperforms 96.88% of its industry peers.
  • GSK had an Average Return On Invested Capital over the past 3 years of 18.48%. This is significantly above the industry average of 13.06%.
  • The last Return On Invested Capital (19.80%) for GSK is above the 3 year average (18.48%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROIC 19.8%
ROA(3y)7.34%
ROA(5y)10.49%
ROE(3y)30.22%
ROE(5y)52.18%
ROIC(3y)18.48%
ROIC(5y)16.49%
GSK Yearly ROA, ROE, ROICGSK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • Looking at the Profit Margin, with a value of 17.50%, GSK belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
  • GSK's Profit Margin has declined in the last couple of years.
  • GSK has a better Operating Margin (28.36%) than 93.75% of its industry peers.
  • In the last couple of years the Operating Margin of GSK has grown nicely.
  • GSK's Gross Margin of 72.67% is amongst the best of the industry. GSK outperforms 80.73% of its industry peers.
  • GSK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.36%
PM (TTM) 17.5%
GM 72.67%
OM growth 3Y0.16%
OM growth 5Y3.17%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
GSK Yearly Profit, Operating, Gross MarginsGSK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. GSK Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GSK is creating value.
  • The number of shares outstanding for GSK has been reduced compared to 1 year ago.
  • GSK has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for GSK is higher compared to a year ago.
GSK Yearly Shares OutstandingGSK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B
GSK Yearly Total Debt VS Total AssetsGSK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • GSK has an Altman-Z score of 2.38. This is not the best score and indicates that GSK is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.38, GSK is doing good in the industry, outperforming 65.63% of the companies in the same industry.
  • GSK has a debt to FCF ratio of 3.73. This is a good value and a sign of high solvency as GSK would need 3.73 years to pay back of all of its debts.
  • GSK's Debt to FCF ratio of 3.73 is amongst the best of the industry. GSK outperforms 87.50% of its industry peers.
  • A Debt/Equity ratio of 0.90 indicates that GSK is somewhat dependend on debt financing.
  • The Debt to Equity ratio of GSK (0.90) is worse than 71.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Altman-Z 2.38
ROIC/WACC2.26
WACC8.77%
GSK Yearly LT Debt VS Equity VS FCFGSK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 0.82 indicates that GSK may have some problems paying its short term obligations.
  • GSK has a worse Current ratio (0.82) than 87.50% of its industry peers.
  • GSK has a Quick Ratio of 0.82. This is a bad value and indicates that GSK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • GSK has a worse Quick ratio (0.54) than 88.02% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.54
GSK Yearly Current Assets VS Current LiabilitesGSK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. GSK Growth Analysis

3.1 Past

  • GSK shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.84%.
  • The Earnings Per Share has been growing slightly by 3.55% on average over the past years.
  • The Revenue has been growing slightly by 4.11% in the past year.
  • The Revenue has been growing slightly by 6.05% on average over the past years.
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%

3.2 Future

  • GSK is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.01% yearly.
  • Based on estimates for the next years, GSK will show a small growth in Revenue. The Revenue will grow by 2.87% on average per year.
EPS Next Y8.66%
EPS Next 2Y8.39%
EPS Next 3Y6.8%
EPS Next 5Y5.01%
Revenue Next Year4.21%
Revenue Next 2Y4.48%
Revenue Next 3Y3.95%
Revenue Next 5Y2.87%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GSK Yearly Revenue VS EstimatesGSK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
GSK Yearly EPS VS EstimatesGSK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. GSK Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 12.24, GSK is valued correctly.
  • Based on the Price/Earnings ratio, GSK is valued cheaply inside the industry as 88.02% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 25.60, GSK is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 11.28, the valuation of GSK can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of GSK indicates a rather cheap valuation: GSK is cheaper than 85.42% of the companies listed in the same industry.
  • GSK is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.84, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.24
Fwd PE 11.28
GSK Price Earnings VS Forward Price EarningsGSK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 90.10% of the companies in the same industry are more expensive than GSK, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, GSK is valued cheaper than 84.90% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.08
EV/EBITDA 8.66
GSK Per share dataGSK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • GSK's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • GSK has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.41
PEG (5Y)3.45
EPS Next 2Y8.39%
EPS Next 3Y6.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. GSK Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.42%, GSK has a reasonable but not impressive dividend return.
  • GSK's Dividend Yield is rather good when compared to the industry average which is at 0.64. GSK pays more dividend than 94.79% of the companies in the same industry.
  • GSK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.88.
Industry RankSector Rank
Dividend Yield 3.42%

5.2 History

  • The dividend of GSK decreases each year by -8.93%.
  • GSK has paid a dividend for at least 10 years, which is a reliable track record.
  • The dividend of GSK decreased recently.
Dividend Growth(5Y)-8.93%
Div Incr Years1
Div Non Decr Years1
GSK Yearly Dividends per shareGSK Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • GSK pays out 44.86% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP44.86%
EPS Next 2Y8.39%
EPS Next 3Y6.8%
GSK Yearly Income VS Free CF VS DividendGSK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B
GSK Dividend Payout.GSK Dividend Payout, showing the Payout Ratio.GSK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

GSK Fundamentals: All Metrics, Ratios and Statistics

GSK PLC-SPON ADR

NYSE:GSK (4/2/2026, 8:04:00 PM)

After market: 56.9 +0.21 (+0.37%)

56.69

+0.7 (+1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)04-29
Inst Owners41.42%
Inst Owner Change181.39%
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap113.56B
Revenue(TTM)32.67B
Net Income(TTM)5.72B
Analysts68.75
Price Target54.76 (-3.4%)
Short Float %0.63%
Short Ratio2.14
Dividend
Industry RankSector Rank
Dividend Yield 3.42%
Yearly Dividend1.69
Dividend Growth(5Y)-8.93%
DP44.86%
Div Incr Years1
Div Non Decr Years1
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.74%
Min EPS beat(2)8.69%
Max EPS beat(2)12.8%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)7.67%
Max EPS beat(4)12.8%
EPS beat(8)8
Avg EPS beat(8)11.8%
EPS beat(12)11
Avg EPS beat(12)9.51%
EPS beat(16)15
Avg EPS beat(16)10.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.76%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-1.6%
Max Revenue beat(4)-0.04%
Revenue beat(8)3
Avg Revenue beat(8)-0.16%
Revenue beat(12)7
Avg Revenue beat(12)1.25%
Revenue beat(16)9
Avg Revenue beat(16)-0.18%
PT rev (1m)0%
PT rev (3m)10.45%
EPS NQ rev (1m)0.05%
EPS NQ rev (3m)-7.38%
EPS NY rev (1m)-0.09%
EPS NY rev (3m)-0.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.7%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)-0.84%
Valuation
Industry RankSector Rank
PE 12.24
Fwd PE 11.28
P/S 2.63
P/FCF 18.08
P/OCF 11.11
P/B 5.25
P/tB N/A
EV/EBITDA 8.66
EPS(TTM)4.63
EY8.17%
EPS(NY)5.03
Fwd EY8.87%
FCF(TTM)3.14
FCFY5.53%
OCF(TTM)5.1
OCFY9%
SpS21.54
BVpS10.8
TBVpS-4.87
PEG (NY)1.41
PEG (5Y)3.45
Graham Number33.54
Profitability
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROCE 23.32%
ROIC 19.8%
ROICexc 21.66%
ROICexgc 62.66%
OM 28.36%
PM (TTM) 17.5%
GM 72.67%
FCFM 14.56%
ROA(3y)7.34%
ROA(5y)10.49%
ROE(3y)30.22%
ROE(5y)52.18%
ROIC(3y)18.48%
ROIC(5y)16.49%
ROICexc(3y)20.55%
ROICexc(5y)19.59%
ROICexgc(3y)56.44%
ROICexgc(5y)71.55%
ROCE(3y)22.36%
ROCE(5y)19.99%
ROICexgc growth 3Y-22.03%
ROICexgc growth 5Y-6.86%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y14.07%
OM growth 3Y0.16%
OM growth 5Y3.17%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
F-Score9
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Debt/EBITDA 1.27
Cap/Depr 129%
Cap/Sales 9.14%
Interest Coverage 13.64
Cash Conversion 66.86%
Profit Quality 83.21%
Current Ratio 0.82
Quick Ratio 0.54
Altman-Z 2.38
F-Score9
WACC8.77%
ROIC/WACC2.26
Cap/Depr(3y)116.02%
Cap/Depr(5y)115.31%
Cap/Sales(3y)8.79%
Cap/Sales(5y)9.19%
Profit Quality(3y)103.9%
Profit Quality(5y)92.12%
High Growth Momentum
Growth
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
EPS Next Y8.66%
EPS Next 2Y8.39%
EPS Next 3Y6.8%
EPS Next 5Y5.01%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%
Revenue Next Year4.21%
Revenue Next 2Y4.48%
Revenue Next 3Y3.95%
Revenue Next 5Y2.87%
EBIT growth 1Y18.74%
EBIT growth 3Y3.83%
EBIT growth 5Y9.41%
EBIT Next Year28.71%
EBIT Next 3Y11.62%
EBIT Next 5Y8.05%
FCF growth 1Y33.15%
FCF growth 3Y-2.59%
FCF growth 5Y-5.17%
OCF growth 1Y18.11%
OCF growth 3Y1.5%
OCF growth 5Y-1.72%

GSK PLC-SPON ADR / GSK Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GSK PLC-SPON ADR?

ChartMill assigns a fundamental rating of 6 / 10 to GSK.


What is the valuation status of GSK PLC-SPON ADR (GSK) stock?

ChartMill assigns a valuation rating of 8 / 10 to GSK PLC-SPON ADR (GSK). This can be considered as Undervalued.


Can you provide the profitability details for GSK PLC-SPON ADR?

GSK PLC-SPON ADR (GSK) has a profitability rating of 9 / 10.


What is the valuation of GSK PLC-SPON ADR based on its PE and PB ratios?

The Price/Earnings (PE) ratio for GSK PLC-SPON ADR (GSK) is 12.24 and the Price/Book (PB) ratio is 5.25.


Can you provide the expected EPS growth for GSK stock?

The Earnings per Share (EPS) of GSK PLC-SPON ADR (GSK) is expected to grow by 8.66% in the next year.